This company listing is no longer active
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Medlab Clinical 過去の業績
過去 基準チェック /06
Medlab Clinical's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 19.2% per year.
主要情報
-18.9%
収益成長率
-7.9%
EPS成長率
Biotechs 業界の成長 | 9.6% |
収益成長率 | -19.2% |
株主資本利益率 | -108.3% |
ネット・マージン | -541.7% |
前回の決算情報 | 30 Jun 2022 |
最近の業績更新
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22収支内訳
Medlab Clinical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 22 | 2 | -8 | 12 | 2 |
31 Mar 22 | 1 | -9 | 9 | 1 |
31 Dec 21 | 4 | -12 | 11 | 1 |
30 Sep 21 | 4 | -12 | 11 | 2 |
30 Jun 21 | 1 | -10 | 11 | 2 |
31 Mar 21 | 1 | -10 | 10 | 2 |
31 Dec 20 | 1 | -11 | 9 | 2 |
30 Sep 20 | 2 | -12 | 9 | 2 |
30 Jun 20 | 3 | -13 | 10 | 2 |
31 Mar 20 | 4 | -12 | 10 | 2 |
31 Dec 19 | 4 | -12 | 11 | 2 |
30 Sep 19 | 5 | -10 | 10 | 1 |
30 Jun 19 | 5 | -8 | 10 | 1 |
31 Mar 19 | 5 | -7 | 8 | 1 |
31 Dec 18 | 5 | -6 | 7 | 0 |
30 Sep 18 | 4 | -5 | 7 | 0 |
30 Jun 18 | 4 | -5 | 6 | 0 |
31 Mar 18 | 4 | -4 | 6 | 0 |
31 Dec 17 | 5 | -4 | 6 | 0 |
30 Sep 17 | 5 | -4 | 5 | 0 |
30 Jun 17 | 4 | -4 | 5 | 0 |
31 Mar 17 | 4 | -4 | 5 | 0 |
31 Dec 16 | 4 | -4 | 4 | 0 |
30 Sep 16 | 3 | -4 | 4 | 0 |
30 Jun 16 | 3 | -3 | 4 | 0 |
質の高い収益: MDC is currently unprofitable.
利益率の向上: MDC is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
成長の加速: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.2%).
株主資本利益率
高いROE: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.